MILLIGAN JOHN F Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
2
Insider Buys Sum
$4.62M
Insider Sells Quantity
53
Insider Sells Sum
$490.24M

Insider Activity of MILLIGAN JOHN F

Biography of MILLIGAN JOHN F

Dr. John F. Milligan, age 58, has made significant contributions to the biotechnology and pharmaceutical industries throughout his impressive career. He holds a Ph.D. in Biochemistry from the University of Illinois and a B.A. in Chemistry from Ohio Wesleyan University. Milligan's career is marked by an extraordinary tenure at Gilead Sciences, Inc., where he joined in 1990 and ascended through various pivotal roles. At Gilead, Milligan served as President and COO before being appointed CEO in 2016, steering the company through a period of remarkable growth and innovation. Under his leadership, he oversaw the development and commercialization of transformative therapies in HIV and hepatitis C, significantly impacting global health. His strategic vision propelled Gilead to the forefront of biopharmaceutical research and development, securing its reputation as a leader in the field. In addition to his influential work at Gilead, Milligan is an insider at 4D Molecular Therapeutics, Inc. His expertise in therapeutic development and strategic management has been instrumental in advancing the company's mission to create targeted gene therapies. His tenure in these prominent organizations underscores his dedication to pioneering health solutions and his role as a trailblazer in biotechnology. Milligan's career is marked by a blend of scientific acumen and executive leadership, solidifying his legacy in the industry.

Disclaimer: This text is generated by a neural network based on open data from the Internet. In case of errors, please send an email to feedback@prismo.pro

2025-07-11SaleAppian Corporation
APPN
10 percent owner
2,008
0.0028%
$30.12$60,481-4.75%
2025-07-11SaleDoximity, Inc.
DOCS
director
5,000
0.0027%
$60.04$300,200+0.27%
2025-07-11SaleFreshworks Inc.
FRSH
director
4,685
0.0016%
$14.27$66,855-1.54%
2025-07-11SaleThe Greenbrier Companies, Inc.
GBX
director
3,652
0.012%
$54.31$198,341-1.11%
2025-07-11SaleHagerty, Inc.
HGTY
director
9,970
0.0109%
$9.94$99,102+0.6%
2025-07-11SaleOxbridge Re Holdings Limited
OXBR
10 percent owner
2,000
0.0255%
$2.22$4,447+5.25%
2025-07-11SaleUiPath Inc.
PATH
CEO and Chairman
45,000
0.0087%
$12.71$572,094-2.86%
2025-07-11SaleTucows Inc.
TCX
Chief Executive Officer
700
0.0064%
$22.86$16,002-0.48%
2025-07-11SaleT-Mobile US, Inc.
TMUS
69,840
0.0061%
$227.55$15.89M+0.09%
2025-07-10SaleAkero Therapeutics, Inc.
AKRO
President and CEO
30,000
0.037%
$51.16$1.53M+2.28%
2025-07-10SaleAstera Labs, Inc. Common Stock
ALAB
Chief Executive Officer
7,522
0.0048%
$102.46$770,709+3.97%
2025-07-10SaleAlexander & Baldwin, Inc.
ALEX
Exec. VP, External Affairs
700
0.001%
$17.93$12,552-0.89%
2025-07-10SaleAlignment Healthcare, Inc.
ALHC
Chief Executive Officer
180,000
0.0912%
$13.41$2.41M-1.08%
2025-07-10SaleAppian Corporation
APPN
10 percent owner
87,039
0.1181%
$30.72$2.67M-3.72%
2025-07-10SaleSalesforce, Inc.
CRM
Chair and CEO
2,250
0.0002%
$266.16$598,854-2.85%
2025-07-10SaleContango Ore, Inc.
CTGO
director
1,818
0.0147%
$20.23$36,778+0.1%
2025-07-10SaleCarvana Co.
CVNA
10 percent owner
100,000
0.0476%
$352.36$35.24M-0.12%
2025-07-10SaleDonaldson Company, Inc.
DCI
Chairman, President and CEO
45,808
0.0394%
$71.71$3.28M-1.8%
2025-07-10SaleDICK'S Sporting Goods, Inc.
DKS
EVP, Chief Financial Officer
9,303
0.0116%
$215.00$2M-1.85%
2025-07-10SaleH.B. Fuller Company
FUL
VP, Corporate Controller
9,546
0.0177%
$64.30$613,852-2.59%
Total: 830153
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.